| Dr Jessica Slim, MD, MPH | |
|
3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 | |
| (503) 494-7551 | |
| (503) 494-4997 |
| Full Name | Dr Jessica Slim |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 3181 Sw Sam Jackson Park Rd, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013274570 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD182845 (Oregon) | Primary |
| 207P00000X | Emergency Medicine | 207P00000X (Colorado) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Health Portland | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portland Adventist Medical Center | 3274908819 | 221 |
| Tuality Medical Group Llc | 7416173414 | 245 |
| The Vancouver Clinic Inc Ps | 3173436490 | 471 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Tuality Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275591984 PECOS PAC ID: 3678486107 Enrollment ID: O20040130000359 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Portland Adventist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215910302 PECOS PAC ID: 7012827876 Enrollment ID: O20040226000131 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Northwest Acute Care Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215983200 PECOS PAC ID: 7012807373 Enrollment ID: O20040318001535 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Tuality Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073929782 PECOS PAC ID: 7416173414 Enrollment ID: O20140729000238 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Entity Name | Portland Adventist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750091021 PECOS PAC ID: 3274908819 Enrollment ID: O20230412001327 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Slim, MD, MPH 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 494-7551 | Dr Jessica Slim, MD, MPH 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 494-7551 |
News Archive
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division, who discuss "family planning and reproductive health issues, including new innovations and promising technologies still in the research stage."
Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 8 days ago
Kimberly Lauren Imbesi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8211 Fax: 503-346-8021 | |
Dr. Hani Darwich, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10123 Se Market St, Portland, OR 97216 Phone: 503-252-2004 | |
Dr. Robert Thomas Martin, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-297-6334 Fax: 503-297-2360 | |
Robert Barriatua, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10123 Se Market St, Portland, OR 97216 Phone: 503-252-2004 | |
Carolyn N Rhett, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1015 Nw 22nd Ave, Portland, OR 97210 Phone: 503-413-7260 | |
Dr. Ross Emery Bryan Iv, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Ohsu Dept Of Emergency Medicine Cdw-em, Portland, OR 97239 Phone: 503-494-1270 |